infigratinib
Showing 1 - 9 of 9
Cholangiocarcinoma, Liver Cancer Trial in Houston (Infigratinib, Atezolizumab, Bevacizumab)
Not yet recruiting
- Cholangiocarcinoma
- Liver Cancer
- Infigratinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)
Active, not recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Infigratinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)
Recruiting
- Achondroplasia
- Infigratinib
-
Parkville, Victoria, Australia
- +3 more
Apr 5, 2022
Glioma, Glioblastoma, GBM Trial in Chandler, Phoenix, Scottsdale (Infigratinib)
Recruiting
- Glioma
- +2 more
- Infigratinib
-
Chandler, Arizona
- +2 more
Mar 10, 2022
Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)
Recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
- Infigratinib
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 15, 2022
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)
Recruiting
- Breast Cancer
- +3 more
- Infigratinib
- +3 more
-
Stanford, CaliforniaStanford University
Feb 16, 2022
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)
Not yet recruiting
- Advanced Solid Tumor
- +2 more
- Infigratinib
-
Palo Alto, California
- +9 more
Aug 2, 2022
Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)
Withdrawn
- Bladder Transitional Cell Carcinoma
- +2 more
- Infigratinib
- (no location specified)
Aug 8, 2022
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer Trial in Worldwide (Infigratinib, Placebo)
Recruiting
- Upper Tract Urothelial Carcinomas
- Urothelial Bladder Cancer
- Infigratinib
- Placebo
-
Tucson, Arizona
- +133 more
Apr 25, 2022